Skip to main content

Table 4 Summary of Cox regression model for PFS with treatment, PIK3CA mutation, PTEN low, and interaction adjusting for stratification factors

From: Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

Covariate

HR (95% CI)

Two-sidedPvalue

PIK3CA mutation a

Treatment (Lap + Pac/Pbo + Pac) (n = 171)

0.41 (0.27, 0.62)

<0.0001

HR status (negative/positive)

0.86 (0.62, 1.20)

0.379

Metastatic sites (visceral/nonvisceral only)

0.77 (0.50, 1.17)

0.218

PIK3CA mutation (yes/no)

1.31 (0.84, 2.07)

0.238

Treatmenta PIK3CA interaction

1.76 (0.91, 3.43)

0.095

PTEN low

Treatment (Lap + Pac/Pbo + Pac) (n = 355)

0.59 (0.42, 0.83)

0.003

HR status (negative/positive)

1.01 (0.81, 1.26)

0.948

Metastatic sites (visceral/nonvisceral only)

0.66 (0.48, 0.89)

0.007

PTEN low (yes/no)

1.10 (0.81, 1.52)

0.537

Treatmenta PTEN low interaction

0.75 (0.48, 1.18)

0.219

  1. aPatients with a PIK3CA indeterminate tumor status were excluded. CI, confidence interval; HR, hazard ratio; Lap, lapatinib; Pac, paclitaxel; Pbo, placebo; PIK3CA, phosphatidylinositol 3-kinase subunit alpha gene; PTEN, phosphatase and tensin homolog.